Therapeutic Approach in Bone Metastasis

*Hiroko Nishida

Department of Pathology, Keio University, Japan

Submission: March 25, 2017; Published: April 04, 2017

Correspondence Address: Hiroko Nishida, Department of Pathology, Keio University, School of Medicine, 35 Shinanomachi, Shinjuku-ku, 160-8582, Japan, Tel: +81-3-5363-3785; Fax:+81-3-3353-3290; Email: hiroko@keio.jp

Abstract

The interaction between tumor cells and their surrounding cells in the bone marrow (BM) microenvironment promotes tumor cell growth and its associated bone destruction in osteolytic bone metastasis. Osteolytic bone disease, characterized by bone pain, increased risk of pathologic fractures, tumor-induced hypercalcemia, is a frequent complication of patients with advanced cancer including breast cancer, prostate cancer, lung cancer and multiple myeloma (MM). These skeletal-related events (SREs) decrease their quality of life (QOL) and reduce their survival. Understanding pathogenesis of bone metastasis has resulted in the development of bone-targeted therapy including bisphosphonates and receptor activator of nuclear factor kappa-B ligand (RANKL) inhibitor. Therapeutic strategies targeting the interaction between tumor cells and cellular components including osteoclasts (OCs) in the BM microenvironments is necessary not only to attain tumor regression but to prevent or delay the incidence of SREs and to improve the QOL in affected patients.

Keywords: Osteolytic Bone Metastasis; Skeletal-Related Events; Quality of Life; Osteoclast; Bone-Targeted Therapy

Abbreviations: BM: Bone Marrow; SREs: Skeletal-Related Events; MM: Multiple Myeloma; QOL: quality of Life; RANKL: Receptor Activator Of Nuclear Factor Kappa-B Ligand; OC: Osteoclast; OB: Osteoblasts; FFPS: Farnesyl Pyrophosphate Synthetase; ONJ: Osteonecrosis of the Jaw

Introduction

The bone is a common site of metastasis in patients with advanced cancer such as breast cancer, prostate cancer, lung cancer and multiple myeloma (MM) [1-3]. Patients with osteolytic bone metastasis frequently experience pathological fractures, spinal cord compression or hypercalcemia, known as skeletal related events (SREs), which lead to bone pain and a decreased quality of life (QOL) [1-3]. The frequency of SREs depends on the characteristics of bone lesions, locations, the number of lesions, or the treatment complications and its occurrence is reported to be 80-90% of patients with breast cancer or MM and 30-40% of lung cancer patients [4-6]. Tumor cells promote osteoclast (OC) formation in association with BM stromal cells, whereas inhibits osteoblast (OB) formation, leading to the bone destruction. Thus, the interaction between tumor cells and their surrounding cells in the bone marrow (BM) leads to the vicious cycle to expand tumor cells and destructive bone lesions [1-3]. Therefore, novel therapeutic approach targeting the interaction between tumor cells and BM microenvironment is necessary not only to attain tumor regression but also to reduce bone destruction and improve patient outcome [1-3].

Bone Targeting Therapy in Osteolytic Bone Metastasis

Current therapeutic options of bone destruction in osteolytic bone metastasis include intravenous bisphosphonates, surgical procedures, radiotherapy and the treatments towards the tumor itself.

Bisphosphonates are currently administrated as the part of the treatments in osteolytic bone metastasis including breast cancer, prostate cancer, lung cancer and MM to delay or prevent the occurrence of SREs and hypercalcemia [7-10]. The mechanism of action of nitrogen containing bisphosphonates such as zoledronic acid and pamidronates suppress farnesyl pyrophosphate synthetase (FPPS), the enzyme in the mevalonate pathway and block prenylate GTPase signaling. As a result, they keep high affinity for bone mineral through their similarity to pyrophosphates and inhibit bone resorption mainly by inducing apoptosis of mature OCs [11]. In addition, they are shown to inhibit tumor cell adhesion to the extracellular matrix and prevent invasion or metastasis in solid tumors [7-10]. Recent reports suggest that zoledronic acid has been to be effective in prolonging time to the first SRE in advanced cancer and bone metastasis [12-14]. However, in other cases, SREs still occur after the treatment with zoledronic acid. Zoledronic acid exacerbate the renal impairment [15] and causes the osteonecrosis of the jaw (ONJ) [16]. Therefore, in several cases, alternative therapeutic approach is needed, further to reduce the occurrence of SREs without these drug toxicities.
Denosumab is a fully human monoclonal antibody which binds RANKL with high specificity and inhibit RANKL-RANK signaling. It acts on BM microenvironment and suppress OC bone resorptive activity by interfering with OC development from OC precursor cells, which leads to the incidence of SREs. Recently, several trials have shown that denosumab was superior to zoledronic acid in delaying or preventing the occurrence of SREs, with median progression free and overall survival similar to zolendronic acid in osteolytic bone disease including advanced breast cancer, prostate cancer and lung cancer [17-24]. Initial dose adjustments of zoledronic acid is necessary for patients who had baseline creatinine clearance lower than 60mL/min. On the other hands, they are not required for denosumab. Hypocalcemia is seen more frequently with denosumab than with zoledronic acid. However, it is manageable with appropriate supplementation with oral calcium and vitamin D [17,20,21].

CD26 is preferentially expressed in normal OCs and is intensely expressed in OCs with osteolytic bone metastasis including breast cancer, osteosarcoma, adenocarcinoma such as lung cancer, and MM [25]. Humanized anti-CD26 monoclonal antibody blocks OC differentiation during early phase of human OC development via the blockade of MKK3/6-p38MAPK-mi/Mif signaling pathway in OC precursor cells. In the future, anti-CD26 antibody may have therapeutic approach for the treatment of osteolytic metastasis to reduce the occurrence of total SREs [25].

Conclusion

Novel agents targeting osteolytic bone lesions seem to be promising therapeutic strategies to delay or prevent SREs for the treatment of MM. Further elucidation of the molecular mechanism of cellular interactions between tumor cells and BM microenvironment will provide us with novel therapeutic approaches which have dramatic effects on the bone destruction with osteolytic bone tumors.

Reference

1. Rodmann GD (2004) Mechanisms of bone metastasis. New Eng J Med 350:1655-1664.
2. Rodman GD (2009) Pathogenesis of myeloma bone disease. Leukemia 23(3): 435-441.
3. Mundy GR (1997) Mechanism of bone metastasis. Cancer 80(8 Suppl): 1546-1556.
4. Irelle A, Cocciolone V, Cannita K, Zugaro L, Di Stasio M, et al. (2016) Bone targeted therapy for preventing skeletal-related events in metastatic breast cancer. Bone 87:169-175.
5. LeVasseur N, Clemens M, Hutton B, Shorr R, Jacobs C (2016) Bone-targeted therapy use in patients with bone metastases from lung cancer: A systematic review of randomized controlled trials. Can Treat Rev 50: 183-193.
6. Silbermann R, Rodman GD (2013) Myeloma bone disease: pathophysiology and management. Ann Oncol 2(2): 59-69.
7. Terpos E, Rodman GD, Dimopoulos MA (2013) Optimal use of bisphosphonates in patients with multiple myeloma. Blood 121(17): 3325-3328.
8. Rosen LS, Gordon D, Kaminski M, Seaman JJ, Chen BL, et al. (2001) Zoledronic acid versus pamidronate in the treatment of skeletal metastases in patients with breast cancer or osteolytic lesion of multiple myeloma. A phase III, double-blind, comparative trial Cancer J 7(5): 377-387.
9. Rosen LS, Gordon D, Kaminski M, Chen BL, Seaman JJ, et al. (2003) Long-term efficacy and safety of zoledronic acid compared with pamidronate disodium in the treatment of skeletal complications with advanced multiple myeloma or breast carcinoma: A randomized, double-blind multicenter, comparative trial. Cancer 98(8): 1735-1744.
10. Saad F, Chen YM, Gleason DM, Chiu J (2007) Continuing benefit of zoledronic acid in preventing skeletal complications in patients with bone metastases. Clin Genitourin Cancer 56(6): 390-396.
11. Guise TA, Chirgwin JM (2003) Role of bisphosphonates in prostate cancer bone metastasis. Semin Oncol 30(5): 717-723.
12. Rosen LS, Gordon D, Tchekmedyan NS, Reitzma D, Seaman J, et al. (2004) Long-term efficacy and safety of zoledronic acid in the treatment of skeletal metastases in patients with non small cell lung cancer and other solid tumors: A randomized, Phase III, double-blind, placebo-controlled trial. Cancer 100(12): 2613-2621.
13. Saad F, Gleason DM, Murray R, Tchekmedyan S, Venner P, et al. (2002) A randomized, placebo-controlled trial o zoledronic acid in patients with hormone-refractory metastatic prostate carcinoma. J Natl Cancer Inst 94(19):1458-1468.
14. Kohno N, Aogi K, Mimami H, Ohashi Y, Takashima S, et al. (2005) Zoledronic acid significantly reduces skeletal complications compared with placebo in Japanese woman with bone metastases from breast cancer: A randomized, placebo-controlled trial. J Clin Oncol 23(15): 3314-3321.
15. Chang JT, Green L, Beitz J (2003) Renal failure with the use of zoledronic acid. N Eng J Med 349(17): 1676-1679.
16. Walter C, Al-Nawas B, Frichkofen N, Knut A Grötz, Walfried Wagner, et al. (2010) Prevalence of bisphosphonates associated osteonecrosis of the jaws in multiple myeloma patients. Head Face Med 6:11.
17. Stopeck AT, Lipton A, Body JJ, Dansey R, Jun S, et al. (2010) Denosumab compared with zoledronic acid or the treatment of bone metastasis in patients with advanced breast cancer: a randomized, double-blind study. J Clin Oncol 28(35): 5132-5139.
18. Irelle A, Cocciolone V, Cannita K Ricevuto E, Ficorella C, et al. (2016) Bone targeted therapy for preventing skeletal-related events in metastatic breast cancer. Bone 87:169-175.
19. Castellano D, Sepulveda JM, Escobar IG, Sundkv A, Cortes-Funes H, et al. (2011) The role of RANKL-ligand inhibition in cancer: the story of denosumab. The Oncologist 16(2): 136-145.
20. Body JJ, Facon T, Coleman RE, Peterson MC, Bekker PJ, et al. (2006) A study of the biological receptor activator of nuclear factor-kappaB ligand inhibitor, denosumab, in patients with multiple myeloma or bone metastases from breast cancer: Clin Cancer Res 12(4):1221-1228.
21. Fitzai K, Carducci M, Smith M, Tadros S, Dansey R, et al. (2011) Denosumab versus zoledronic acid for the treatment of bone metastases in men with castration-resistant prostate cancer: a randomized, double-blind study. Lancet 377(9768): 813-822.
22. Hutton B, Morretto P, Emmenegger U. (2013) Bone-targeted agent use for bone metastases from breast cancer and prostate cancer: A patient survey. J Bone Oncol 2(3): 105-109.
23. LeVasseur N, Clemens M, Hutton B, Shorr R, Jacobs C (2016) Bone-targeted therapy use in patients with bone metastases from lung cancer: A systematic review of randomized controlled trials. Cancer Treat Rev 50: 183-193.

How to cite this article: Hiroko N. Therapeutic Approach in Bone Metastasis. Canc Therapy & Oncol Int J. 2017; 4(1): 555629. DOI: 10.19080/CTOIJ.2017.04.555629.
24. Henry DH, Costa L, Goldwasser F, von Moos R, Wilkenbacher W, et al. (2011) Randomized, double-blind study of denosumab versus zoledronic acid in the treatment of bone metastasis in patients with advanced cancer (excluding breast and prostate cancer) or multiple myeloma. J Clin Oncol 29(9): 1125-1132.

25. Nishida H, Suzuki H, Madokoro H, Sakamoto M, Yamada T, et al. (2014) Blockade of CD26 signaling inhibits human osteoclast development. J Bone Miner Res 29(11): 2439-2455.

This work is licensed under Creative Commons Attribution 4.0 License

DOI: 10.19080/CTOIJ.2017.04.555629

Your next submission with Juniper Publishers will reach you the below assets

- Quality Editorial service
- Swift Peer Review
- Reprints availability
- E-prints Service
- Manuscript Podcast for convenient understanding
- Global attainment for your research
- Manuscript accessibility in different formats (Pdf, E-pub, Full Text, Audio)
- Unceasing customer service

Track the below URL for one-step submission

https://juniperpublishers.com/online-submission.php